Turinabol

Chlorodehydromethyltestosterone (CDMT), marketed as Oral Turinabol, is a synthetic anabolic-androgenic steroid (AAS) first synthesized by chemist Albert Stachowiak at Jenapharm in the German Democratic Republic and patented in 1961. The compound is the 4-chloro-substituted derivative of metandienone (Dianabol), combining structural elements of clostebol (4-chlorotestosterone) and metandienone (1,2-dehydro-17alpha-methyltestosterone). The 4-chloro substitution at the A-ring prevents aromatization to estrogenic metabolites, while the 1,2-dehydro modification and the 17alpha-methyl group confer oral bioavailability and a dissociated anabolic-to-androgenic ratio of approximately 54:6 relative to methyltestosterone. Introduced for clinical use in 1965 for the treatment of muscle wasting disorders, osteoporosis, and recovery from debilitating illness, CDMT was prescribed at therapeutic doses of 5 to 10 mg in the published literature in adults and 1 to 2.5 mg in the published literature in women and children [1, 2].

The compound occupies a singular position in pharmacological and sporting history as the principal agent of State Plan Topic 14.25 (Staatsplanthema 14.25), the systematic doping program administered by the German Democratic Republic's Sports Medical Service from 1974 through 1989, under which approximately ten thousand athletes received CDMT, frequently without informed consent and often described to recipients as vitamins [3, 4]. The program produced a generation of international athletic dominance and a subsequent generation of adverse health consequences in exposed athletes, including hepatotoxicity, endocrine disruption, virilization in female athletes, and cardiovascular morbidity. Production was discontinued by Jenapharm in 1994, and the compound holds no current marketing authorization in any jurisdiction.

Pharmacokinetically, CDMT is characterized by complete oral absorption, hepatic first-pass metabolism through multiple cytochrome P450 pathways (principally CYP3A4 for 6beta-hydroxylation and mitochondrial CYP11A1, CYP11B1, and CYP11B2 for 11beta-hydroxylation and additional oxidative transformations), and a plasma elimination half-life of approximately 16 hours [5, 6, 7]. The compound produces extensive phase I and phase II metabolites, with approximately 50 urinary metabolites identified. Of particular significance to anti-doping science, the long-term metabolite 4-chloro-18-nor-17beta-hydroxymethyl,17alpha-methyl-5beta-androst-13-en-3alpha-ol, identified by Schanzer and colleagues and subsequently confirmed in controlled human administration studies, extends the urinary detection window to 40 to 50 days after a single dose and potentially longer with chronic administration, enabling retrospective detection of CDMT use in athletes [8, 9, 10].

The pharmacology of CDMT is that of a moderate-affinity androgen receptor agonist with strong dissociation between anabolic (nitrogen-retentive, myotrophic) and androgenic (virilizing, sebotropic) activities. The compound does not undergo 5alpha-reduction to more potent androgens, does not serve as an aromatase substrate, and binds sex hormone-binding globulin (SHBG) with sufficient affinity to displace endogenous androgens and elevate free testosterone fractions in the presence of concurrent testosterone [11]. The principal adverse effects are dose-dependent hepatotoxicity (consistent with the 17alpha-alkylated steroid class), suppression of the hypothalamic-pituitary-gonadal axis with reduction of luteinizing hormone, follicle-stimulating hormone, and endogenous testosterone production, unfavorable alterations in serum lipid profiles (suppression of high-density lipoprotein cholesterol and elevation of low-density lipoprotein cholesterol), and, in female subjects, irreversible virilization at supratherapeutic doses [12, 13]. This monograph reviews the chemistry, synthesis, and structural pharmacology of CDMT; the receptor-level mechanism of action; the comprehensive metabolic and pharmacokinetic profile including anti-doping detection science; the preclinical pharmacology; the limited clinical evidence base; sourcing and quality considerations; reconstitution and handling; stack interactions; adverse events and safety signals; and a structured comparative assessment of five alternative oral anabolic-androgenic steroids against CDMT on five competency standards.